Xiaoping Su
Impact in
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Cancer Genomics and Diagnostics 33
- Cancer-related molecular mechanisms research 12
- Oncology 42
- Cancer Immunotherapy and Biomarkers 21
- Co-authors
- James R. Downing (17 shared papers)Charles Grenfell Mullighan (15 shared papers)Christopher B. Miller (7 shared papers)Jing Ma (9 shared papers)Sheila A. Shurtleff (8 shared papers)Ching‐Hon Pui (6 shared papers)Elaine Coustan‐Smith (4 shared papers)Xuetao Cao (9 shared papers)
- Journals
- Blood (23 papers)Nature Communications (17 papers)Nature (9 papers)Cancer Cell (7 papers)Oncotarget (7 papers)
- Partner nations
- United StatesChinaFrance
In The Last Decade
Xiaoping Su
209 papers receiving 30.7k citations
Xiaoping Su's Hit Papers
Peers
Comparison fields: 5 of 154
- Cancer Research 6.9k
- Oncology 4.4k
- Hepatology 1.3k
- Hematology 1.9k
- Genetics 1.2k
Countries citing papers authored by Xiaoping Su
This map shows the geographic impact of Xiaoping Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Su more than expected).
Fields of papers citing papers by Xiaoping Su
This network shows the impact of papers produced by Xiaoping Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Su. The network helps show where Xiaoping Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaoping Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 219 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2401 |
| 2 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2169 |
| 3 | Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma Hit paper breakdown → | 2017 | 1989 |
| 4 | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer Hit paper breakdown → | 2017 | 1951 |
| 5 | Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia Hit paper breakdown → | 2007 | 1488 |
| 6 | Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia Hit paper breakdown → | 2009 | 1179 |
| 7 | PD-L1 Expression in Triple-Negative Breast Cancer Hit paper breakdown → | 2014 | 1158 |
| 8 | Circular RNA circMTO1 acts as the sponge of microRNA‐9 to suppress hepatocellular carcinoma progression Hit paper breakdown → | 2017 | 966 |
| 9 | Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Hit paper breakdown → | 2009 | 794 |
| 10 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 730 |
| 11 | 2005 | 680 | |
| 12 | Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 Hit paper breakdown → | 2015 | 678 |
| 13 | Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia Hit paper breakdown → | 2008 | 660 |
| 14 | Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia Hit paper breakdown → | 2012 | 582 |
| 15 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 564 |
| 16 | 2006 | 525 | |
| 17 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 489 |
| 18 | JAK mutations in high-risk childhood acute lymphoblastic leukemia Hit paper breakdown → | 2009 | 470 |
| 19 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes Hit paper breakdown → | 2020 | 428 |
| 20 | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer Hit paper breakdown → | 2018 | 359 |
About Xiaoping Su
Xiaoping Su is a scholar working on Cancer Research, Oncology, Hematology, Molecular Biology and Immunology, having authored 219 papers that have together received 31.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (33 papers), Acute Myeloid Leukemia Research (22 papers), Cancer Immunotherapy and Biomarkers (21 papers), Acute Lymphoblastic Leukemia research (18 papers), Renal cell carcinoma treatment (17 papers), Immunotherapy and Immune Responses (13 papers), Cancer-related molecular mechanisms research (12 papers) and Chromatin Remodeling and Cancer (9 papers). The work is most often cited by research in Cancer Research (6.9k citations), Oncology (4.4k citations), Hepatology (1.3k citations), Hematology (1.9k citations) and Genetics (1.2k citations). Xiaoping Su has collaborated with scholars based in United States, China and France. Frequent co-authors include James R. Downing, Charles Grenfell Mullighan, Christopher B. Miller, Jing Ma, Sheila A. Shurtleff, Ching‐Hon Pui, Elaine Coustan‐Smith, Xuetao Cao, Letha A. Phillips and James Dalton. Their work appears in journals such as Blood, Nature Communications, Nature, Cancer Cell and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.